SmartTarget device for the detection of prostate cancer

The SmartTarget technology enables image-directed tumour targeting during minimally invasive biopsy procedures for prostate cancer patients.

The CE certified SmartTarget system is an image fusion device for guiding targeted, transperineal prostate biopsy. Designed and developed by biomedical engineers at UCL and urologists at NHS Trust hospital University College London Hospital (UCLH), the technology enables image-directed tumour targeting during minimally invasive biopsy procedures for prostate cancer patients and has undergone extensive clinical evaluation in over 200 patients at UCLH.

Led by Professor Mark Emberton, Dean of the UCL Faculty of Medical Sciences, and Professor Caroline Moore (UCL Division of Surgery & Interventional Science), the research demonstrated that the use of multi-parametric MRI (mpMRI) as an alternative method is much more effective and significantly cuts NHS costs.